[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gi-bleeding\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gi-bleeding":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100504755","evaluation-of-the-clinical-utility-of-endoscopic-closure-using-a-dual-action-tissue-dat-clip-100504755",false,"NCT05852457","Evaluation of the Clinical Utility of Endoscopic Closure Using a Dual Action Tissue (DAT) Clip","Prospective Evaluation of the Clinical Utility of Endoscopic Closure Using a Dual Action Tissue (DAT) Clip","Inclusion Criteria:\n\n* Age 18 years or older.\n* Patients scheduled to undergo endoscopic procedures as part of their routine care in which endoscopic clip closure is clinically indicated:\n\nTreatment of bleeding Treatment of perforation and\u002For fistulas Tissue approximation for mucosal gaps associated with endoscopic resection (e.g., endoscopic mucosal resection, endoscopic submucosal dissection) or third space endoscopy (e.g., peroral endoscopic myotomy in the gastrointestinal tract)\n\nExclusion Criteria:\n\n* Any contraindications to performing endoscopy.\n* Participants in another research protocol that could interfere or influence the outcomes measures of the present study.","ALL","18 Years",{"count":19,"type":20},250,"ESTIMATED","OBSERVATIONAL","This study is designed as a multicenter prospective data recording study to document the performance of the DAT clip as part of standard medical care of patients. No experimental interventions will be performed.",[24,25,26,27,28,29],"GI Bleeding","Perforation Colon","Perforation Bowel","Perforation Duodenal","Perforated Bowel","Fistula","RECRUITING","2025-10-07",{"date":33,"type":34},"2025-10-08","ACTUAL",{"date":36,"type":34},"2022-08-31",{"date":38,"type":20},"2027-12",{"name":40,"class":41},"AdventHealth","OTHER",2,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":4},"100607087","hematological-disorders-in-patients-with-gi-angiodysplasia-100607087","NCT07183995","Hematological Disorders in Patients With GI Angiodysplasia","Hematological Disorders in Patients With Gastrointestinal Angiodysplasia","Inclusion Criteria:\n\nAdults (above 18 years) and elderly Both genders Admitted to GIT Unit with manifestations of GIT bleeding diagnosed by upper endoscopy and Colonoscopy as angiodyplasia.\n\n\\-\n\nExclusion Criteria:\n\nother causes of GIT bleeding\n\n\\-",{"count":51,"type":20},55,"The aim of this study will be to assess the association between GIT angiodysplasia with any hematological disorders as von Willebrand factor and Prognostic value of von Willebrand factor on patient's outcomes as risk of rebleeding and hospital mortality",[24],"NOT_YET_RECRUITING","2025-09-22",{"date":57,"type":34},"2025-09-25",{"date":59,"type":20},"2025-09",{"date":61,"type":20},"2027-08",{"name":63,"class":41},"Assiut University",{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":78,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":42},"100392795","high-dose-oral-omeprazole-in-high-risk-ugib-100392795","NCT04394663","High Dose Oral Omeprazole in High Risk UGIB","High Dose Oral Omeprazole Versus Standard Continuous Intravenous Pantoprazole in Patient With Peptic Ulcer Bleeding and Undergo Successful Therapeutic Endoscopy; Non-inferiority Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with peptic ulcer bleeding and endoscopic finding show ulcer with Forrest classification Ia (spurting haemorrhage), IIa (oozing haemorrhage), Ib (non-bleeding visible vessel)\n* Age \\> 18 years old\n\nExclusion Criteria:\n\n* Deny to participate\n* Pregnancy or lactation\n* Low risk peptic ulcer bleeding including clean base ulcer, flat pigmented spot\n* Non-peptic ulcer bleeding eg. erosive gastritis\u002Fduodenitis, Mallory Weiss tear, esophageal\u002Fgastric\u002Fduodenal varices, vascular lesions (eg. Dieulafoy) , malignant ulcer\n* Bleeding tendency\n* Terminal stage of cancer\n* ESRD on hemodialysis\n* Decompensated liver cirrhosis",{"count":72,"type":20},128,"INTERVENTIONAL",[75],"NA","Peptic ulcer bleeding is the most common etiology in upper gastrointestinal bleeding all over the world. After endoscopic treatment, proton pump inhibitor (PPI) is recommended to prevent re-bleeding. Intravenous PPI is recommended as a standard treatment. In the past, there were many trials showing the efficacy of high-dose oral PPI after endoscopic hemostasis but most were industrial sponsor which assessing an expensive PPI. Moreover, the number of patients in those studies were insufficient to confirm a non-inferiority outcome in term of rebleeding by using oral PPI. This study will evaluate a high-dose, local-made PPI (omeprazole) in peptic ulcer treatment after successful endoscopic hemostasis compared to standard IV PPI continuous drip in term of rebleeding, as well as 24-hour gastric pH monitoring.",[24],[79],"oral proton pump inhibitor","2025-09-12",{"date":82,"type":34},"2025-09-18",{"date":84,"type":34},"2020-10-01",{"date":86,"type":20},"2025-12-31",{"name":88,"class":41},"King Chulalongkorn Memorial Hospital"]